{"gene":"MRPL49","run_date":"2026-04-28T18:30:28","timeline":{"discoveries":[{"year":1996,"finding":"The human NOF gene (later identified as MRPL49), located at chromosome 11q13 immediately adjacent to FAU in a head-to-head configuration, encodes a conserved protein of 166 amino acids that is proline-rich. Its mRNA (~2.2 kb) is ubiquitously expressed, and the protein shows >80% identity to mouse and rat orthologs. The gene spans ~5 kb with 4 exons/3 introns and is not disrupted by a t(11;17)(q13;q21) translocation associated with B-non-Hodgkin lymphoma.","method":"cDNA cloning, genomic Southern blotting, northern blotting, chromosomal mapping, sequence analysis","journal":"Genomics","confidence":"Medium","confidence_rationale":"Tier 2 — direct molecular characterization of the gene/cDNA, single lab, multiple complementary methods","pmids":["8786148"],"is_preprint":false},{"year":2001,"finding":"MRPL49 (MRP-L49) was identified as one of 48 distinct proteins comprising the large subunit (39S) of the mammalian mitochondrial ribosome. It was identified by proteolytic digestion of whole 39S subunits followed by LC-MS/MS peptide sequencing and EST database searching, establishing it as a bona fide structural component of the mt-LSU.","method":"Proteolytic digestion of purified 39S subunits, liquid chromatography–mass spectrometry (LC-MS/MS), EST database searching","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 — direct biochemical identification from purified organellar complex, rigorous proteomics","pmids":["11551941"],"is_preprint":false},{"year":2014,"finding":"Cryo-EM structure of the human mitochondrial large ribosomal subunit (mt-LSU) at 3.4 Å resolution revealed MRPL49 as one of 48 proteins in the 39S subunit, including 21 mitochondria-specific proteins. The structure showed extensive remodeling of the central protuberance and adaptations of the exit tunnel for hydrophobic nascent peptides, providing the structural context for MRPL49's role as an integral mt-LSU component.","method":"Single-particle cryo-electron microscopy (cryo-EM) at 3.4 Å resolution","journal":"Science","confidence":"High","confidence_rationale":"Tier 1 — near-atomic resolution structure of the complex containing MRPL49, published in high-impact journal","pmids":["25278503"],"is_preprint":false},{"year":2017,"finding":"Cryo-EM structures of two late-stage assembly intermediates of the human mt-LSU (~3 Å resolution) isolated from native cell pools revealed the timing of rRNA folding and protein incorporation during mitoribosomal maturation. MRPL49 is present as an integral structural component of the mt-LSU in these assembly states, and comparison of intermediates provided insight into the sequential steps of large subunit biogenesis.","method":"Single-particle cryo-EM (~3 Å), native isolation of assembly intermediates from human cell line","journal":"Nature structural & molecular biology","confidence":"High","confidence_rationale":"Tier 1 — near-atomic resolution structures of native assembly intermediates, multiple states compared","pmids":["28892042"],"is_preprint":false},{"year":2020,"finding":"BioID proximity-labeling using 100 mitochondrial baits in human cells placed MRPL49 within the high-confidence mitochondrial proximity interaction network, consistent with its localization to the mitochondrial matrix as part of the large mitoribosomal subunit. MRPL49 was detected as a proximity interactor of other mt-LSU proteins, supporting its stable integration into the 39S subunit in the mitochondrial compartment.","method":"BioID proximity-dependent biotinylation with 100 mitochondrial baits, mass spectrometry","journal":"Cell metabolism","confidence":"Medium","confidence_rationale":"Tier 2 — systematic proximity labeling with mitochondrial baits, large-scale but indirect localization evidence","pmids":["32877691"],"is_preprint":false},{"year":2025,"finding":"Bi-allelic loss-of-function variants in MRPL49 cause combined oxidative phosphorylation deficiency (COXPD). Complexome profiling of patient fibroblasts demonstrated reduced steady-state levels of both small and large mitochondrial ribosomal subunits (with a more pronounced reduction of the mt-LSU), without evidence of altered mitoribosomal assembly intermediates. This ribosomal insufficiency results in reduced levels of OXPHOS complexes I and IV, consistent with impaired mitochondrial translation. Clinical presentations ranged from Perrault syndrome (sensorineural hearing loss + primary ovarian insufficiency) to severe childhood-onset leukodystrophy, microcephaly, and retinal dystrophy.","method":"Genome sequencing, complexome profiling of patient fibroblasts, OXPHOS enzyme complex quantification, clinical phenotyping of nine unrelated families","journal":"American journal of human genetics","confidence":"High","confidence_rationale":"Tier 2 — complexome profiling with functional OXPHOS readout in patient cells, replicated across nine families, multiple orthogonal methods","pmids":["40043708"],"is_preprint":false}],"current_model":"MRPL49 is an integral structural protein of the human mitochondrial ribosome large subunit (mt-LSU/39S), essential for maintaining normal steady-state levels of mt-LSU and mt-SSU; bi-allelic loss-of-function variants reduce mitoribosomal subunit levels and impair mitochondrial translation, causing combined oxidative phosphorylation deficiency (reduced complexes I and IV) and multisystem disease including Perrault syndrome and leukodystrophy."},"narrative":{"teleology":[{"year":1996,"claim":"Initial cloning of the NOF gene (later MRPL49) established it as a ubiquitously expressed, evolutionarily conserved 166-amino-acid proline-rich protein at chromosome 11q13, but its molecular function was unknown.","evidence":"cDNA cloning, northern blotting, genomic mapping, and cross-species sequence comparison","pmids":["8786148"],"confidence":"Medium","gaps":["No functional assignment; protein was not linked to any complex or organelle","Single-lab characterization without independent confirmation"]},{"year":2001,"claim":"Mass spectrometric identification of MRPL49 as a bona fide subunit of the purified mammalian 39S mitochondrial ribosomal subunit resolved its molecular role, placing it in the mitochondrial translation machinery.","evidence":"Proteolytic digestion of purified bovine 39S mt-LSU followed by LC-MS/MS peptide sequencing","pmids":["11551941"],"confidence":"High","gaps":["Precise position within the mt-LSU structure was unknown","Functional consequence of MRPL49 loss had not been tested"]},{"year":2014,"claim":"Near-atomic cryo-EM structures of the human mt-LSU provided the first structural context for MRPL49 within the 39S subunit, revealing how mitochondria-specific proteins remodel the ribosomal architecture.","evidence":"Single-particle cryo-EM at 3.4 Å resolution of the human mt-LSU","pmids":["25278503"],"confidence":"High","gaps":["MRPL49-specific protein–protein or protein–rRNA contacts not individually described","Role during ribosome assembly versus function was unclear"]},{"year":2017,"claim":"Cryo-EM of native late-stage mt-LSU assembly intermediates showed that MRPL49 is already incorporated at these stages, defining its temporal placement in the biogenesis pathway.","evidence":"Single-particle cryo-EM (~3 Å) of natively isolated human mt-LSU assembly intermediates","pmids":["28892042"],"confidence":"High","gaps":["Whether MRPL49 is required for progression through assembly checkpoints was not tested","Earliest assembly intermediate in which MRPL49 is incorporated was not determined"]},{"year":2025,"claim":"Human genetic and biochemical evidence demonstrated that MRPL49 is essential for mitoribosomal stability and mitochondrial translation: bi-allelic loss-of-function variants cause reduced mt-LSU and mt-SSU levels, combined OXPHOS deficiency (complexes I and IV), and clinically manifest as Perrault syndrome or leukodystrophy.","evidence":"Genome sequencing in nine unrelated families, complexome profiling and OXPHOS quantification in patient fibroblasts","pmids":["40043708"],"confidence":"High","gaps":["Whether the mt-SSU reduction is a secondary consequence of mt-LSU instability or an independent effect is unresolved","No rescue experiment (complementation with wild-type MRPL49) was reported","Mechanism by which specific OXPHOS complexes (I and IV but not others) are preferentially affected is not explained"]},{"year":null,"claim":"The precise molecular contacts of MRPL49 within the mt-LSU, its contributions to specific ribosome assembly steps, and the basis for tissue-selective disease manifestations remain uncharacterized.","evidence":"","pmids":[],"confidence":"Low","gaps":["No high-resolution map of MRPL49-specific rRNA or protein contacts","No conditional knockout or depletion model to dissect assembly versus translation functions","Genotype-phenotype correlation (Perrault syndrome vs. leukodystrophy) not mechanistically explained"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0005198","term_label":"structural molecule activity","supporting_discovery_ids":[1,2,3]}],"localization":[{"term_id":"GO:0005739","term_label":"mitochondrion","supporting_discovery_ids":[1,2,3,4]},{"term_id":"GO:0005840","term_label":"ribosome","supporting_discovery_ids":[1,2,3]}],"pathway":[{"term_id":"R-HSA-392499","term_label":"Metabolism of proteins","supporting_discovery_ids":[1,2,5]},{"term_id":"R-HSA-1852241","term_label":"Organelle biogenesis and maintenance","supporting_discovery_ids":[3]}],"complexes":["39S mitochondrial ribosomal large subunit (mt-LSU)"],"partners":[],"other_free_text":[]},"mechanistic_narrative":"MRPL49 is a structural protein of the human mitochondrial large ribosomal subunit (39S/mt-LSU), where it serves as one of ~48 integral components required for mitoribosomal integrity and mitochondrial translation. Proteomic identification from purified 39S subunits and cryo-EM structures at near-atomic resolution confirm its stable incorporation into the mt-LSU, including in late-stage assembly intermediates [PMID:11551941, PMID:25278503, PMID:28892042]. Bi-allelic loss-of-function variants in MRPL49 reduce steady-state levels of both mitoribosomal subunits—particularly the mt-LSU—leading to combined oxidative phosphorylation deficiency (decreased complexes I and IV) and multisystem disease including Perrault syndrome and childhood-onset leukodystrophy [PMID:40043708]."},"prefetch_data":{"uniprot":{"accession":"Q13405","full_name":"Large ribosomal subunit protein mL49","aliases":["39S ribosomal protein L49, mitochondrial","L49mt","MRP-L49","Neighbor of FAU","NOF","Protein NOF1"],"length_aa":166,"mass_kda":19.2,"function":"","subcellular_location":"Mitochondrion","url":"https://www.uniprot.org/uniprotkb/Q13405/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":true,"resolved_as":"","url":"https://depmap.org/portal/gene/MRPL49","classification":"Common Essential","n_dependent_lines":1010,"n_total_lines":1208,"dependency_fraction":0.8360927152317881},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/MRPL49","total_profiled":1310},"omim":[{"mim_id":"621195","title":"COMBINED OXIDATIVE PHOSPHORYLATION DEFICIENCY 60; COXPD60","url":"https://www.omim.org/entry/621195"},{"mim_id":"609060","title":"COMBINED OXIDATIVE PHOSPHORYLATION DEFICIENCY 1; COXPD1","url":"https://www.omim.org/entry/609060"},{"mim_id":"606866","title":"MITOCHONDRIAL RIBOSOMAL PROTEIN L49; MRPL49","url":"https://www.omim.org/entry/606866"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"","locations":[],"tissue_specificity":"Low tissue specificity","tissue_distribution":"Detected in all","driving_tissues":[],"url":"https://www.proteinatlas.org/search/MRPL49"},"hgnc":{"alias_symbol":["NOF","NOF1","L49mt","mL49"],"prev_symbol":["C11orf4"]},"alphafold":{"accession":"Q13405","domains":[{"cath_id":"3.30.780.10","chopping":"40-166","consensus_level":"medium","plddt":94.8146,"start":40,"end":166}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/Q13405","model_url":"https://alphafold.ebi.ac.uk/files/AF-Q13405-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-Q13405-F1-predicted_aligned_error_v6.png","plddt_mean":84.56},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=MRPL49","jax_strain_url":"https://www.jax.org/strain/search?query=MRPL49"},"sequence":{"accession":"Q13405","fasta_url":"https://rest.uniprot.org/uniprotkb/Q13405.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/Q13405/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/Q13405"}},"corpus_meta":[{"pmid":"24737272","id":"PMC_24737272","title":"N-of-1 (single-patient) trials for statin-related myalgia.","date":"2014","source":"Annals of internal medicine","url":"https://pubmed.ncbi.nlm.nih.gov/24737272","citation_count":92,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"12533607","id":"PMC_12533607","title":"Light stimulates a transducin-independent increase of cytoplasmic Ca2+ and suppression of current in cones from the zebrafish mutant nof.","date":"2003","source":"The Journal of neuroscience : the official journal of the Society for Neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/12533607","citation_count":82,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"34607609","id":"PMC_34607609","title":"Molecular profiling of advanced malignancies guides first-line N-of-1 treatments in the I-PREDICT treatment-naïve study.","date":"2021","source":"Genome medicine","url":"https://pubmed.ncbi.nlm.nih.gov/34607609","citation_count":76,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"17251445","id":"PMC_17251445","title":"Identification of a zebrafish cone photoreceptor-specific promoter and genetic rescue of achromatopsia in the nof mutant.","date":"2007","source":"Investigative ophthalmology & visual science","url":"https://pubmed.ncbi.nlm.nih.gov/17251445","citation_count":72,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"25989944","id":"PMC_25989944","title":"PCSK9 inhibitors and neurocognitive adverse events: exploring the FDA directive and a proposal for N-of-1 trials.","date":"2015","source":"Drug safety","url":"https://pubmed.ncbi.nlm.nih.gov/25989944","citation_count":56,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"36516128","id":"PMC_36516128","title":"Consensus Guidelines for the Design and In Vitro Preclinical Efficacy Testing N-of-1 Exon Skipping Antisense Oligonucleotides.","date":"2022","source":"Nucleic acid therapeutics","url":"https://pubmed.ncbi.nlm.nih.gov/36516128","citation_count":40,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"1988463","id":"PMC_1988463","title":"Purification and characterization of an 82-kD membrane protein as a neurite outgrowth factor binding protein: possible involvement of NOF binding protein in axonal outgrowth in developing retina.","date":"1991","source":"The Journal of cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/1988463","citation_count":35,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"20877469","id":"PMC_20877469","title":"NOF1 encodes an Arabidopsis protein involved in the control of rRNA expression.","date":"2010","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/20877469","citation_count":34,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"16052316","id":"PMC_16052316","title":"A pilot study of ondansetron plus metopimazine vs. ondansetron monotherapy in children receiving highly emetogenic chemotherapy: a Bayesian randomized serial N-of-1 trials design.","date":"2005","source":"Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer","url":"https://pubmed.ncbi.nlm.nih.gov/16052316","citation_count":29,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"39496921","id":"PMC_39496921","title":"The state-of-the-art of N-of-1 therapies and the IRDiRC N-of-1 development roadmap.","date":"2024","source":"Nature reviews. Drug discovery","url":"https://pubmed.ncbi.nlm.nih.gov/39496921","citation_count":23,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"23283428","id":"PMC_23283428","title":"Simvastatin decreases levodopa-induced dyskinesia in monkeys, but not in a randomized, placebo-controlled, multiple cross-over (\"n-of-1\") exploratory trial of simvastatin against levodopa-induced dyskinesia in Parkinson's disease patients.","date":"2012","source":"Parkinsonism & related disorders","url":"https://pubmed.ncbi.nlm.nih.gov/23283428","citation_count":23,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"34255080","id":"PMC_34255080","title":"Individual Postprandial Glycemic Responses to Diet in n-of-1 Trials: Westlake N-of-1 Trials for Macronutrient Intake (WE-MACNUTR).","date":"2021","source":"The Journal of nutrition","url":"https://pubmed.ncbi.nlm.nih.gov/34255080","citation_count":21,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"39532857","id":"PMC_39532857","title":"A framework for N-of-1 trials of individualized gene-targeted therapies for genetic diseases.","date":"2024","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/39532857","citation_count":19,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"28815218","id":"PMC_28815218","title":"Capturing the systemic immune signature of a norovirus infection: an n-of-1 case study within a clinical trial.","date":"2017","source":"Wellcome open research","url":"https://pubmed.ncbi.nlm.nih.gov/28815218","citation_count":19,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"2174013","id":"PMC_2174013","title":"Characterization of the FB-NOF transposable element of Drosophila melanogaster.","date":"1990","source":"Genetics","url":"https://pubmed.ncbi.nlm.nih.gov/2174013","citation_count":18,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"29203402","id":"PMC_29203402","title":"Lamin A expression in circulating osteoprogenitors as a potential biomarker for frailty: The Nepean Osteoporosis and Frailty (NOF) Study.","date":"2017","source":"Experimental gerontology","url":"https://pubmed.ncbi.nlm.nih.gov/29203402","citation_count":17,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"38484408","id":"PMC_38484408","title":"Tumor-agnostic baskets to N-of-1 platform trials and real-world data: Transforming precision oncology clinical trial design.","date":"2024","source":"Cancer treatment reviews","url":"https://pubmed.ncbi.nlm.nih.gov/38484408","citation_count":14,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"23798052","id":"PMC_23798052","title":"Discovery-based nutritional systems biology: developing N-of-1 nutrigenomic research.","date":"2012","source":"International journal for vitamin and nutrition research. Internationale Zeitschrift fur Vitamin- und Ernahrungsforschung. Journal international de vitaminologie et de nutrition","url":"https://pubmed.ncbi.nlm.nih.gov/23798052","citation_count":14,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"35787784","id":"PMC_35787784","title":"Genomic landscape of lymphatic malformations: a case series and response to the PI3Kα inhibitor alpelisib in an N-of-1 clinical trial.","date":"2022","source":"eLife","url":"https://pubmed.ncbi.nlm.nih.gov/35787784","citation_count":13,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"33855906","id":"PMC_33855906","title":"The effect of a color tattoo on the local skin redox regulatory network: an N-of-1 study.","date":"2021","source":"Free radical research","url":"https://pubmed.ncbi.nlm.nih.gov/33855906","citation_count":10,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"27473188","id":"PMC_27473188","title":"Efficacy of ultra-micronized palmitoylethanolamide (um-PEA) in geriatric patients with chronic pain: study protocol for a series of N-of-1 randomized trials.","date":"2016","source":"Trials","url":"https://pubmed.ncbi.nlm.nih.gov/27473188","citation_count":10,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"25989980","id":"PMC_25989980","title":"OncoRep: an n-of-1 reporting tool to support genome-guided treatment for breast cancer patients using RNA-sequencing.","date":"2015","source":"BMC medical genomics","url":"https://pubmed.ncbi.nlm.nih.gov/25989980","citation_count":9,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"32281737","id":"PMC_32281737","title":"Ataluren/ivacaftor combination therapy: Two N-of-1 trials in cystic fibrosis patients with nonsense mutations.","date":"2020","source":"Pediatric pulmonology","url":"https://pubmed.ncbi.nlm.nih.gov/32281737","citation_count":9,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"26746195","id":"PMC_26746195","title":"Comparative effectiveness of antihypertensive treatment for older children with primary hypertension: study protocol for a series of n-of-1 randomized trials.","date":"2016","source":"Trials","url":"https://pubmed.ncbi.nlm.nih.gov/26746195","citation_count":8,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"28552011","id":"PMC_28552011","title":"Testing for differentially expressed genetic pathways with single-subject N-of-1 data in the presence of inter-gene correlation.","date":"2017","source":"Statistical methods in medical research","url":"https://pubmed.ncbi.nlm.nih.gov/28552011","citation_count":7,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"38527301","id":"PMC_38527301","title":"N-of-1 medicine.","date":"2024","source":"Singapore medical journal","url":"https://pubmed.ncbi.nlm.nih.gov/38527301","citation_count":6,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"23685284","id":"PMC_23685284","title":"FB-NOF is a non-autonomous transposable element, expressed in Drosophila melanogaster and present only in the melanogaster group.","date":"2013","source":"Gene","url":"https://pubmed.ncbi.nlm.nih.gov/23685284","citation_count":5,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"8786148","id":"PMC_8786148","title":"Isolation, cDNA, and genomic structure of a conserved gene (NOF) at chromosome 11q13 next to FAU and oriented in the opposite transcriptional orientation.","date":"1996","source":"Genomics","url":"https://pubmed.ncbi.nlm.nih.gov/8786148","citation_count":5,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"27705967","id":"PMC_27705967","title":"Evaluating the Utility of a 'N-of-1' Precision Cancer Medicine Strategy: The Case for 'Time-to-Subsequent-Disease Progression'.","date":"2016","source":"Oncology","url":"https://pubmed.ncbi.nlm.nih.gov/27705967","citation_count":5,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"40043708","id":"PMC_40043708","title":"Bi-allelic variants in MRPL49 cause variable clinical presentations, including sensorineural hearing loss, leukodystrophy, and ovarian insufficiency.","date":"2025","source":"American journal of human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/40043708","citation_count":4,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"40014258","id":"PMC_40014258","title":"Toward an Extensible Regulatory Framework for N-of-1 to N-of-Few Personalized RNA Therapy Design.","date":"2025","source":"Therapeutic innovation & regulatory science","url":"https://pubmed.ncbi.nlm.nih.gov/40014258","citation_count":4,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"40524218","id":"PMC_40524218","title":"Blueprint for clinical N-of-1 strategies with off-label precision treatments in monogenic epilepsies.","date":"2025","source":"Orphanet journal of rare diseases","url":"https://pubmed.ncbi.nlm.nih.gov/40524218","citation_count":4,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"30451538","id":"PMC_30451538","title":"A Pilot Study of Amino Acids in Unresectable Non-Small-Cell Lung Cancer Patients During Chemotherapy: A Randomized Serial N-of-1 Trials Design.","date":"2018","source":"Nutrition and cancer","url":"https://pubmed.ncbi.nlm.nih.gov/30451538","citation_count":3,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"16333669","id":"PMC_16333669","title":"An FB-NOF mediated duplication of the white gene is responsible for the zeste1 phenotype in some Drosophila melanogaster unstable strains.","date":"2005","source":"Molecular genetics and genomics : MGG","url":"https://pubmed.ncbi.nlm.nih.gov/16333669","citation_count":3,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"38144875","id":"PMC_38144875","title":"Effectiveness of L-serine supplementation in children with a GRIN2B loss-of-function mutation: Rationale and protocol for single patient (n-of-1) multiple cross-over trials.","date":"2023","source":"Contemporary clinical trials communications","url":"https://pubmed.ncbi.nlm.nih.gov/38144875","citation_count":3,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"38214417","id":"PMC_38214417","title":"Rethinking the transfusion pathway in myelodysplastic syndromes: Study protocol for a novel randomized feasibility n-of-1 trial of weekly-interval red cell transfusion in myelodysplastic syndromes.","date":"2024","source":"Transfusion","url":"https://pubmed.ncbi.nlm.nih.gov/38214417","citation_count":2,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"38881838","id":"PMC_38881838","title":"N-of-1 health optimization: Digital monitoring of biomarker dynamics to gamify adherence to metabolic switching.","date":"2024","source":"PNAS nexus","url":"https://pubmed.ncbi.nlm.nih.gov/38881838","citation_count":2,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"41006236","id":"PMC_41006236","title":"Hypoxic conditioning in Parkinson's disease: randomized controlled multiple N-of-1 trials.","date":"2025","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/41006236","citation_count":2,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"36697023","id":"PMC_36697023","title":"Complete and sustained remission of hypercortisolism with pasireotide treatment of an adrenocorticotropic hormone (ACTH)-secreting thoracic neuroendocrine tumor: an n-of-1 trial.","date":"2023","source":"Endocrine journal","url":"https://pubmed.ncbi.nlm.nih.gov/36697023","citation_count":2,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"40142856","id":"PMC_40142856","title":"Efficacy and Safety of Photobiomodulation in MELAS: Protocol for a Series of N-of-1 Trials.","date":"2025","source":"Journal of clinical medicine","url":"https://pubmed.ncbi.nlm.nih.gov/40142856","citation_count":2,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"38170057","id":"PMC_38170057","title":"The importance of personalization in high altitude protocols for hematologic and metabolic benefits in sports: A multi-dimensional N-of-1 case study.","date":"2023","source":"Heliyon","url":"https://pubmed.ncbi.nlm.nih.gov/38170057","citation_count":2,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"34841890","id":"PMC_34841890","title":"Results of a 5-Year N-of-1 Growth Hormone Releasing Hormone Gene Therapy Experiment.","date":"2021","source":"Rejuvenation research","url":"https://pubmed.ncbi.nlm.nih.gov/34841890","citation_count":2,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"39417135","id":"PMC_39417135","title":"Biallelic variants in MRPL49 cause variable clinical presentations, including sensorineural hearing loss, leukodystrophy, and ovarian insufficiency.","date":"2024","source":"medRxiv : the preprint server for health sciences","url":"https://pubmed.ncbi.nlm.nih.gov/39417135","citation_count":1,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"41898852","id":"PMC_41898852","title":"From Genomic Diagnosis to Personalized RNA Medicine: Advances in Next-Generation Sequencing and N-of-1 Antisense Oligonucleotide Therapies for Rare Genetic Diseases.","date":"2026","source":"Genes","url":"https://pubmed.ncbi.nlm.nih.gov/41898852","citation_count":0,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"41256339","id":"PMC_41256339","title":"Rethinking p16, p53, and HPV in HNCSCC through lessons from glioblastoma subclonal evolution toward patient-centric N-of-1 single-cell RNA sequencing paradigm.","date":"2025","source":"World journal of clinical cases","url":"https://pubmed.ncbi.nlm.nih.gov/41256339","citation_count":0,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"41999155","id":"PMC_41999155","title":"An n-of-1 gene-directed drug repurposing trial for an ultrarare genetic condition.","date":"2026","source":"Epilepsia","url":"https://pubmed.ncbi.nlm.nih.gov/41999155","citation_count":0,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"40374022","id":"PMC_40374022","title":"Athlete burnout and biomarkers: An exploratory, longitudinal N-of-1 study.","date":"2025","source":"Psychology of sport and exercise","url":"https://pubmed.ncbi.nlm.nih.gov/40374022","citation_count":0,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"1701872","id":"PMC_1701872","title":"Possible involvement of neurite outgrowth factor (NOF) receptor in axonal outgrowth from developing chick retina.","date":"1990","source":"Neuroscience research. Supplement : the official journal of the Japan Neuroscience Society","url":"https://pubmed.ncbi.nlm.nih.gov/1701872","citation_count":0,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"40720011","id":"PMC_40720011","title":"Milasen: The Emerging Era of Patient-Customized N-of-1 Antisense Oligonucleotides as Therapeutic Agents for Genetic Diseases.","date":"2025","source":"Methods in molecular biology (Clifton, N.J.)","url":"https://pubmed.ncbi.nlm.nih.gov/40720011","citation_count":0,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"37830320","id":"PMC_37830320","title":"[Cystic fibrosis - ETI and type 2 N-of-1 trials : the next step].","date":"2023","source":"Revue medicale de Liege","url":"https://pubmed.ncbi.nlm.nih.gov/37830320","citation_count":0,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"41265180","id":"PMC_41265180","title":"Potential benefits of l-serine in children with GRIN2B loss-of-function variants: Randomized n-of-1 trials.","date":"2025","source":"Molecular genetics and metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/41265180","citation_count":0,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"38533474","id":"PMC_38533474","title":"Corrigendum to \"Effectiveness of L-serine supplementation in children with a GRIN2B loss-of-function mutation: Rationale and protocol for single patient (n-of-1) multiple cross-over trials\" [Contemp. Clin. Trials Commun. 36 (2023)/ DOI: 10.1016/j.conctc.2023.101233].","date":"2024","source":"Contemporary clinical trials communications","url":"https://pubmed.ncbi.nlm.nih.gov/38533474","citation_count":0,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"40700673","id":"PMC_40700673","title":"Personalized N-of-1 Combination Therapies for Advanced Gastrointestinal Stromal Tumors.","date":"2025","source":"JCO precision oncology","url":"https://pubmed.ncbi.nlm.nih.gov/40700673","citation_count":0,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"41831434","id":"PMC_41831434","title":"Matching hallmarks of cancer complexity with N-of-1 precision oncology.","date":"2026","source":"Med (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/41831434","citation_count":0,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"42028575","id":"PMC_42028575","title":"From N-of-1 to versatility in propionic acidemia: Antisense oligonucleotide-mediated skipping of a constitutive PCCA pseudoexon.","date":"2026","source":"Molecular therapy. Nucleic acids","url":"https://pubmed.ncbi.nlm.nih.gov/42028575","citation_count":0,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":null,"id":"bio_10.1101_2024.10.10.24315152","title":"Biallelic variants in<i>MRPL49</i>cause variable clinical presentations, including sensorineural hearing loss, leukodystrophy, and ovarian insufficiency","date":"2024-10-11","source":"bioRxiv","url":"https://doi.org/10.1101/2024.10.10.24315152","citation_count":0,"is_preprint":true,"source_track":"pubmed_title"},{"pmid":"22658674","id":"PMC_22658674","title":"Insights into RNA biology from an atlas of mammalian mRNA-binding proteins.","date":"2012","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/22658674","citation_count":1718,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"12477932","id":"PMC_12477932","title":"Generation and initial analysis of more than 15,000 full-length human and mouse cDNA sequences.","date":"2002","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/12477932","citation_count":1479,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"26186194","id":"PMC_26186194","title":"The BioPlex Network: A Systematic Exploration of the Human Interactome.","date":"2015","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/26186194","citation_count":1118,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"28514442","id":"PMC_28514442","title":"Architecture of the human interactome defines protein communities and disease networks.","date":"2017","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/28514442","citation_count":1085,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"26496610","id":"PMC_26496610","title":"A human interactome in three quantitative dimensions organized by stoichiometries and abundances.","date":"2015","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/26496610","citation_count":1015,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"19490893","id":"PMC_19490893","title":"A genome-wide RNAi screen identifies multiple synthetic lethal interactions with the Ras oncogene.","date":"2009","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/19490893","citation_count":843,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"14702039","id":"PMC_14702039","title":"Complete sequencing and characterization of 21,243 full-length human cDNAs.","date":"2003","source":"Nature genetics","url":"https://pubmed.ncbi.nlm.nih.gov/14702039","citation_count":754,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"33961781","id":"PMC_33961781","title":"Dual proteome-scale networks reveal cell-specific remodeling of the human interactome.","date":"2021","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/33961781","citation_count":705,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"22939629","id":"PMC_22939629","title":"A census of human soluble protein complexes.","date":"2012","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/22939629","citation_count":689,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"21873635","id":"PMC_21873635","title":"Phylogenetic-based propagation of functional annotations within the Gene Ontology consortium.","date":"2011","source":"Briefings in bioinformatics","url":"https://pubmed.ncbi.nlm.nih.gov/21873635","citation_count":656,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"15489334","id":"PMC_15489334","title":"The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).","date":"2004","source":"Genome research","url":"https://pubmed.ncbi.nlm.nih.gov/15489334","citation_count":438,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"16344560","id":"PMC_16344560","title":"Diversification of transcriptional modulation: large-scale identification and characterization of putative alternative promoters of human genes.","date":"2005","source":"Genome research","url":"https://pubmed.ncbi.nlm.nih.gov/16344560","citation_count":409,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"21145461","id":"PMC_21145461","title":"Dynamics of cullin-RING ubiquitin ligase network revealed by systematic quantitative proteomics.","date":"2010","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/21145461","citation_count":318,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"25278503","id":"PMC_25278503","title":"Structure of the large ribosomal subunit from human mitochondria.","date":"2014","source":"Science (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/25278503","citation_count":262,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"34800366","id":"PMC_34800366","title":"Quantitative high-confidence human mitochondrial proteome and its dynamics in cellular context.","date":"2021","source":"Cell metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/34800366","citation_count":239,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"27023846","id":"PMC_27023846","title":"Structure and Function of the Mitochondrial Ribosome.","date":"2016","source":"Annual review of biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/27023846","citation_count":217,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"11551941","id":"PMC_11551941","title":"The large subunit of the mammalian mitochondrial ribosome. Analysis of the complement of ribosomal proteins present.","date":"2001","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/11551941","citation_count":216,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"29568061","id":"PMC_29568061","title":"An AP-MS- and BioID-compatible MAC-tag enables comprehensive mapping of protein interactions and subcellular localizations.","date":"2018","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/29568061","citation_count":201,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"30833792","id":"PMC_30833792","title":"A protein-interaction network of interferon-stimulated genes extends the innate immune system landscape.","date":"2019","source":"Nature immunology","url":"https://pubmed.ncbi.nlm.nih.gov/30833792","citation_count":159,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"20186120","id":"PMC_20186120","title":"A functional peptidyl-tRNA hydrolase, ICT1, has been recruited into the human mitochondrial ribosome.","date":"2010","source":"The EMBO journal","url":"https://pubmed.ncbi.nlm.nih.gov/20186120","citation_count":153,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"25900982","id":"PMC_25900982","title":"BioID-based Identification of Skp Cullin F-box (SCF)β-TrCP1/2 E3 Ligase Substrates.","date":"2015","source":"Molecular & cellular proteomics : MCP","url":"https://pubmed.ncbi.nlm.nih.gov/25900982","citation_count":149,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"32877691","id":"PMC_32877691","title":"A High-Density Human Mitochondrial Proximity Interaction Network.","date":"2020","source":"Cell metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/32877691","citation_count":148,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"31871319","id":"PMC_31871319","title":"Mapping the proximity interaction network of the Rho-family GTPases reveals signalling pathways and regulatory mechanisms.","date":"2019","source":"Nature cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/31871319","citation_count":137,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"28892042","id":"PMC_28892042","title":"Structures of the human mitochondrial ribosome in native states of assembly.","date":"2017","source":"Nature structural & molecular biology","url":"https://pubmed.ncbi.nlm.nih.gov/28892042","citation_count":136,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"27591049","id":"PMC_27591049","title":"SPATA2 Links CYLD to LUBAC, Activates CYLD, and Controls LUBAC Signaling.","date":"2016","source":"Molecular cell","url":"https://pubmed.ncbi.nlm.nih.gov/27591049","citation_count":134,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"21832049","id":"PMC_21832049","title":"Interactions of pathological hallmark proteins: tubulin polymerization promoting protein/p25, beta-amyloid, and alpha-synuclein.","date":"2011","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/21832049","citation_count":131,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"23349634","id":"PMC_23349634","title":"A newly uncovered group of distantly related lysine methyltransferases preferentially interact with molecular chaperones to regulate their activity.","date":"2013","source":"PLoS genetics","url":"https://pubmed.ncbi.nlm.nih.gov/23349634","citation_count":131,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"35140242","id":"PMC_35140242","title":"Human transcription factor protein interaction networks.","date":"2022","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/35140242","citation_count":123,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"26725010","id":"PMC_26725010","title":"KAP1 Recruitment of the 7SK snRNP Complex to Promoters Enables Transcription Elongation by RNA Polymerase II.","date":"2015","source":"Molecular cell","url":"https://pubmed.ncbi.nlm.nih.gov/26725010","citation_count":113,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"33545068","id":"PMC_33545068","title":"Systematically defining selective autophagy receptor-specific cargo using autophagosome content profiling.","date":"2021","source":"Molecular cell","url":"https://pubmed.ncbi.nlm.nih.gov/33545068","citation_count":105,"is_preprint":false,"source_track":"gene2pubmed"}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":27921,"output_tokens":588,"usd":0.046291},"stage2":{"model":"claude-opus-4-6","input_tokens":3751,"output_tokens":995,"usd":0.065445},"total_usd":0.285764,"stage1_batch_id":"msgbatch_01Mgbec4vM6c9vXht7JVJzss","stage2_batch_id":"msgbatch_01JkuuH5RB2BdJNsgnhjbC6s","note":"batch pricing = 50% of standard","round2_stage1":{"model":"claude-sonnet-4-6","input_tokens":39859,"output_tokens":2279,"usd":0.076881},"round2_rules_fired":"R3","round2_stage2":{"model":"claude-opus-4-6","input_tokens":5133,"output_tokens":1564,"usd":0.097147}},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2025,\n      \"finding\": \"Bi-allelic loss-of-function variants in MRPL49 cause combined oxidative phosphorylation deficiency (COXPD). Complexome profiling of patient fibroblasts revealed reduced steady-state levels of both small and large mitochondrial ribosomal subunits (with a more pronounced reduction of the large subunit), without evidence of altered mitoribosomal assembly, leading to reduced OXPHOS enzyme complexes I and IV.\",\n      \"method\": \"Complexome profiling of patient-derived fibroblasts; genome sequencing; biochemical measurement of OXPHOS enzyme complexes\",\n      \"journal\": \"American journal of human genetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal methods (complexome profiling, OXPHOS enzyme assays, genome sequencing) in patient fibroblasts, replicated across nine unrelated families in peer-reviewed publication\",\n      \"pmids\": [\"40043708\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1996,\n      \"finding\": \"The human NOF (Neighbour of FAU) gene, located at chromosome 11q13 in a head-to-head configuration with FAU, encodes a 166 amino acid proline-rich protein with no homology to known genes. The locus and gene organization are conserved in mouse and rat, where orthologous proteins share >80% identity.\",\n      \"method\": \"cDNA cloning, genomic structure determination, chromosomal mapping, sequence analysis\",\n      \"journal\": \"Genomics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — cDNA and genomic characterization from a single lab; foundational identification of gene structure and conservation\",\n      \"pmids\": [\"8786148\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"MRPL49 encodes a component of the mitochondrial ribosomal large subunit; loss of MRPL49 function reduces steady-state levels of both mitoribosomal subunits (large subunit more severely affected) without disrupting mitoribosomal assembly, resulting in decreased OXPHOS complex I and IV activity and a combined oxidative phosphorylation deficiency (COXPD) with multi-system clinical manifestations.\"\n}\n```\n\n--- ROUND 2 (R2/R3, augmented corpus) ---\n\nI'll classify each paper first, then extract discoveries only from KEEP papers.\n\n**Classification:**\n\n- Papers [1]-[27] in the retrieved corpus (except [28], [30], [43], [56]): Most are about \"N-of-1\" clinical trials, zebrafish \"nof\" mutants, Drosophila \"FB-NOF\" transposable elements, Arabidopsis \"NOF1\", neurite outgrowth factor \"NOF\", Lamin A \"NOF Study\" — all EXCLUDE (alias collisions).\n- Paper [28] retrieved corpus: \"NOF (Neighbour of FAU)\" — this is the human gene at chromosome 11q13. This could be MRPL49's original name, but the abstract describes it as a novel gene with 166 amino acids, proline-rich, no homology to known genes. MRPL49 is a mitochondrial ribosomal protein — need to check if NOF = MRPL49. Actually, MRPL49 (MRP-L49, NOF) is indeed the Neighbour of FAU gene. KEEP.\n- Paper [30] retrieved corpus: Directly about MRPL49 biallelic variants. KEEP.\n- Paper [43] retrieved corpus: Same as [30] but earlier version (medRxiv). KEEP.\n- Paper [56] retrieved corpus: bioRxiv preprint same content as [30]/[43]. KEEP (but superseded by peer-reviewed).\n\n**Gene2pubmed curated papers:**\n- [14] Structure of human mt large ribosomal subunit — includes MRPL49 as component. KEEP.\n- [17] Large subunit of mammalian mitochondrial ribosome protein complement — MRPL49 identified. KEEP.\n- [24] Structures of human mitoribosome assembly intermediates — MRPL49 in structure. KEEP.\n- [16] Review of mitoribosome structure/function — KEEP (context).\n- [20] ICT1 as integral mitoribosome component — KEEP (mt-LSU context).\n- [15] Quantitative human mitochondrial proteome — MRPL49 listed. KEEP.\n- [22] High-density mitochondrial proximity interaction network — MRPL49 as bait/prey. KEEP.\n- [3],[4],[8] BioPlex networks — MRPL49 interactions identified. KEEP.\n- Others ([1],[2],[5],[6],[7],[9]-[13],[18],[19],[21],[23],[25]-[30]) — large-scale studies that may include MRPL49 incidentally, or unrelated. The ones directly relevant to MRPL49 mechanism: KEEP if MRPL49 is specifically discussed.\n\n```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1996,\n      \"finding\": \"The human NOF gene (later identified as MRPL49), located at chromosome 11q13 immediately adjacent to FAU in a head-to-head configuration, encodes a conserved protein of 166 amino acids that is proline-rich. Its mRNA (~2.2 kb) is ubiquitously expressed, and the protein shows >80% identity to mouse and rat orthologs. The gene spans ~5 kb with 4 exons/3 introns and is not disrupted by a t(11;17)(q13;q21) translocation associated with B-non-Hodgkin lymphoma.\",\n      \"method\": \"cDNA cloning, genomic Southern blotting, northern blotting, chromosomal mapping, sequence analysis\",\n      \"journal\": \"Genomics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — direct molecular characterization of the gene/cDNA, single lab, multiple complementary methods\",\n      \"pmids\": [\"8786148\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"MRPL49 (MRP-L49) was identified as one of 48 distinct proteins comprising the large subunit (39S) of the mammalian mitochondrial ribosome. It was identified by proteolytic digestion of whole 39S subunits followed by LC-MS/MS peptide sequencing and EST database searching, establishing it as a bona fide structural component of the mt-LSU.\",\n      \"method\": \"Proteolytic digestion of purified 39S subunits, liquid chromatography–mass spectrometry (LC-MS/MS), EST database searching\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — direct biochemical identification from purified organellar complex, rigorous proteomics\",\n      \"pmids\": [\"11551941\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"Cryo-EM structure of the human mitochondrial large ribosomal subunit (mt-LSU) at 3.4 Å resolution revealed MRPL49 as one of 48 proteins in the 39S subunit, including 21 mitochondria-specific proteins. The structure showed extensive remodeling of the central protuberance and adaptations of the exit tunnel for hydrophobic nascent peptides, providing the structural context for MRPL49's role as an integral mt-LSU component.\",\n      \"method\": \"Single-particle cryo-electron microscopy (cryo-EM) at 3.4 Å resolution\",\n      \"journal\": \"Science\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — near-atomic resolution structure of the complex containing MRPL49, published in high-impact journal\",\n      \"pmids\": [\"25278503\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"Cryo-EM structures of two late-stage assembly intermediates of the human mt-LSU (~3 Å resolution) isolated from native cell pools revealed the timing of rRNA folding and protein incorporation during mitoribosomal maturation. MRPL49 is present as an integral structural component of the mt-LSU in these assembly states, and comparison of intermediates provided insight into the sequential steps of large subunit biogenesis.\",\n      \"method\": \"Single-particle cryo-EM (~3 Å), native isolation of assembly intermediates from human cell line\",\n      \"journal\": \"Nature structural & molecular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — near-atomic resolution structures of native assembly intermediates, multiple states compared\",\n      \"pmids\": [\"28892042\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"BioID proximity-labeling using 100 mitochondrial baits in human cells placed MRPL49 within the high-confidence mitochondrial proximity interaction network, consistent with its localization to the mitochondrial matrix as part of the large mitoribosomal subunit. MRPL49 was detected as a proximity interactor of other mt-LSU proteins, supporting its stable integration into the 39S subunit in the mitochondrial compartment.\",\n      \"method\": \"BioID proximity-dependent biotinylation with 100 mitochondrial baits, mass spectrometry\",\n      \"journal\": \"Cell metabolism\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — systematic proximity labeling with mitochondrial baits, large-scale but indirect localization evidence\",\n      \"pmids\": [\"32877691\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"Bi-allelic loss-of-function variants in MRPL49 cause combined oxidative phosphorylation deficiency (COXPD). Complexome profiling of patient fibroblasts demonstrated reduced steady-state levels of both small and large mitochondrial ribosomal subunits (with a more pronounced reduction of the mt-LSU), without evidence of altered mitoribosomal assembly intermediates. This ribosomal insufficiency results in reduced levels of OXPHOS complexes I and IV, consistent with impaired mitochondrial translation. Clinical presentations ranged from Perrault syndrome (sensorineural hearing loss + primary ovarian insufficiency) to severe childhood-onset leukodystrophy, microcephaly, and retinal dystrophy.\",\n      \"method\": \"Genome sequencing, complexome profiling of patient fibroblasts, OXPHOS enzyme complex quantification, clinical phenotyping of nine unrelated families\",\n      \"journal\": \"American journal of human genetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — complexome profiling with functional OXPHOS readout in patient cells, replicated across nine families, multiple orthogonal methods\",\n      \"pmids\": [\"40043708\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"MRPL49 is an integral structural protein of the human mitochondrial ribosome large subunit (mt-LSU/39S), essential for maintaining normal steady-state levels of mt-LSU and mt-SSU; bi-allelic loss-of-function variants reduce mitoribosomal subunit levels and impair mitochondrial translation, causing combined oxidative phosphorylation deficiency (reduced complexes I and IV) and multisystem disease including Perrault syndrome and leukodystrophy.\"\n}\n```","stage2_raw":"```json\n{\n  \"mechanistic_narrative\": \"MRPL49 encodes a structural component of the mitochondrial ribosomal large subunit (mt-LSU), where it is required for maintaining steady-state levels of both mt-LSU and the small subunit (mt-SSU), with a more pronounced effect on the large subunit [PMID:40043708]. Loss of MRPL49 function does not disrupt mitoribosomal assembly but reduces the abundance of assembled mitoribosomes, leading to decreased activity of OXPHOS complexes I and IV [PMID:40043708]. Bi-allelic loss-of-function variants in MRPL49 cause combined oxidative phosphorylation deficiency (COXPD) with multi-system clinical manifestations, as demonstrated across nine unrelated families [PMID:40043708].\",\n  \"teleology\": [\n    {\n      \"year\": 1996,\n      \"claim\": \"The initial identification of the MRPL49 locus (then called NOF) established its genomic organization at 11q13 in a head-to-head configuration with FAU, encoding a conserved 166-amino-acid proline-rich protein of unknown function.\",\n      \"evidence\": \"cDNA cloning, genomic structure determination, and cross-species sequence analysis in human, mouse, and rat\",\n      \"pmids\": [\"8786148\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"No functional assignment or subcellular localization was determined\",\n        \"No link to the mitochondrial ribosome had been established\"\n      ]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"Patient genetics and biochemistry established that MRPL49 is an essential mt-LSU component whose loss reduces mitoribosomal subunit levels and selectively impairs OXPHOS complexes I and IV, causing a Mendelian combined oxidative phosphorylation deficiency.\",\n      \"evidence\": \"Complexome profiling and OXPHOS enzyme assays in fibroblasts from nine unrelated families with bi-allelic MRPL49 variants, combined with genome sequencing\",\n      \"pmids\": [\"40043708\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"Mechanism by which reduced MRPL49 selectively lowers complex I and IV while sparing other OXPHOS complexes is unknown\",\n        \"No structural model of MRPL49 within the assembled mt-LSU has been reported\",\n        \"No rescue or complementation experiment was described to confirm causality beyond genetic association across families\"\n      ]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"It remains unknown how MRPL49 contributes to mitoribosomal stability at the molecular level — whether it contacts specific rRNA segments or neighboring MRPs — and why its loss reduces both subunits despite being a large-subunit component.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Low\",\n      \"gaps\": [\n        \"No cryo-EM or crosslinking data defining MRPL49 contacts within the mt-LSU\",\n        \"Mechanism linking mt-LSU protein loss to coordinated mt-SSU reduction is unexplained\",\n        \"Tissue-specific pathophysiology of MRPL49-related COXPD is uncharacterized\"\n      ]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0005198\", \"supporting_discovery_ids\": [0]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005739\", \"supporting_discovery_ids\": [0]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-1430728\", \"supporting_discovery_ids\": [0]},\n      {\"term_id\": \"R-HSA-1643685\", \"supporting_discovery_ids\": [0]}\n    ],\n    \"complexes\": [\n      \"mitochondrial ribosome large subunit (mt-LSU)\"\n    ],\n    \"partners\": [],\n    \"other_free_text\": []\n  }\n}\n```\n\n--- ROUND 2 (R2/R3, augmented corpus) ---\n\n```json\n{\n  \"mechanistic_narrative\": \"MRPL49 is a structural protein of the human mitochondrial large ribosomal subunit (39S/mt-LSU), where it serves as one of ~48 integral components required for mitoribosomal integrity and mitochondrial translation. Proteomic identification from purified 39S subunits and cryo-EM structures at near-atomic resolution confirm its stable incorporation into the mt-LSU, including in late-stage assembly intermediates [PMID:11551941, PMID:25278503, PMID:28892042]. Bi-allelic loss-of-function variants in MRPL49 reduce steady-state levels of both mitoribosomal subunits—particularly the mt-LSU—leading to combined oxidative phosphorylation deficiency (decreased complexes I and IV) and multisystem disease including Perrault syndrome and childhood-onset leukodystrophy [PMID:40043708].\",\n  \"teleology\": [\n    {\n      \"year\": 1996,\n      \"claim\": \"Initial cloning of the NOF gene (later MRPL49) established it as a ubiquitously expressed, evolutionarily conserved 166-amino-acid proline-rich protein at chromosome 11q13, but its molecular function was unknown.\",\n      \"evidence\": \"cDNA cloning, northern blotting, genomic mapping, and cross-species sequence comparison\",\n      \"pmids\": [\"8786148\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"No functional assignment; protein was not linked to any complex or organelle\",\n        \"Single-lab characterization without independent confirmation\"\n      ]\n    },\n    {\n      \"year\": 2001,\n      \"claim\": \"Mass spectrometric identification of MRPL49 as a bona fide subunit of the purified mammalian 39S mitochondrial ribosomal subunit resolved its molecular role, placing it in the mitochondrial translation machinery.\",\n      \"evidence\": \"Proteolytic digestion of purified bovine 39S mt-LSU followed by LC-MS/MS peptide sequencing\",\n      \"pmids\": [\"11551941\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"Precise position within the mt-LSU structure was unknown\",\n        \"Functional consequence of MRPL49 loss had not been tested\"\n      ]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Near-atomic cryo-EM structures of the human mt-LSU provided the first structural context for MRPL49 within the 39S subunit, revealing how mitochondria-specific proteins remodel the ribosomal architecture.\",\n      \"evidence\": \"Single-particle cryo-EM at 3.4 Å resolution of the human mt-LSU\",\n      \"pmids\": [\"25278503\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"MRPL49-specific protein–protein or protein–rRNA contacts not individually described\",\n        \"Role during ribosome assembly versus function was unclear\"\n      ]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Cryo-EM of native late-stage mt-LSU assembly intermediates showed that MRPL49 is already incorporated at these stages, defining its temporal placement in the biogenesis pathway.\",\n      \"evidence\": \"Single-particle cryo-EM (~3 Å) of natively isolated human mt-LSU assembly intermediates\",\n      \"pmids\": [\"28892042\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"Whether MRPL49 is required for progression through assembly checkpoints was not tested\",\n        \"Earliest assembly intermediate in which MRPL49 is incorporated was not determined\"\n      ]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"Human genetic and biochemical evidence demonstrated that MRPL49 is essential for mitoribosomal stability and mitochondrial translation: bi-allelic loss-of-function variants cause reduced mt-LSU and mt-SSU levels, combined OXPHOS deficiency (complexes I and IV), and clinically manifest as Perrault syndrome or leukodystrophy.\",\n      \"evidence\": \"Genome sequencing in nine unrelated families, complexome profiling and OXPHOS quantification in patient fibroblasts\",\n      \"pmids\": [\"40043708\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"Whether the mt-SSU reduction is a secondary consequence of mt-LSU instability or an independent effect is unresolved\",\n        \"No rescue experiment (complementation with wild-type MRPL49) was reported\",\n        \"Mechanism by which specific OXPHOS complexes (I and IV but not others) are preferentially affected is not explained\"\n      ]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"The precise molecular contacts of MRPL49 within the mt-LSU, its contributions to specific ribosome assembly steps, and the basis for tissue-selective disease manifestations remain uncharacterized.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Low\",\n      \"gaps\": [\n        \"No high-resolution map of MRPL49-specific rRNA or protein contacts\",\n        \"No conditional knockout or depletion model to dissect assembly versus translation functions\",\n        \"Genotype-phenotype correlation (Perrault syndrome vs. leukodystrophy) not mechanistically explained\"\n      ]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0005198\", \"supporting_discovery_ids\": [1, 2, 3]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005739\", \"supporting_discovery_ids\": [1, 2, 3, 4]},\n      {\"term_id\": \"GO:0005840\", \"supporting_discovery_ids\": [1, 2, 3]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-392499\", \"supporting_discovery_ids\": [1, 2, 5]},\n      {\"term_id\": \"R-HSA-1852241\", \"supporting_discovery_ids\": [3]}\n    ],\n    \"complexes\": [\n      \"39S mitochondrial ribosomal large subunit (mt-LSU)\"\n    ],\n    \"partners\": [],\n    \"other_free_text\": []\n  }\n}\n```"}